YU40502A - 4-piridinil-n-acil-l-fenilalanini - Google Patents

4-piridinil-n-acil-l-fenilalanini

Info

Publication number
YU40502A
YU40502A YU40502A YUP40502A YU40502A YU 40502 A YU40502 A YU 40502A YU 40502 A YU40502 A YU 40502A YU P40502 A YUP40502 A YU P40502A YU 40502 A YU40502 A YU 40502A
Authority
YU
Yugoslavia
Prior art keywords
phenylalanines
pyridinyl
acyl
vcam
binding
Prior art date
Application number
YU40502A
Other languages
English (en)
Inventor
Gerald Lewis Kaplan
Achyutharo Sidduri
Jefferson Wright Tilley
Original Assignee
F.Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag. filed Critical F.Hoffmann-La Roche Ag.
Publication of YU40502A publication Critical patent/YU40502A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Abstract

Jedinjenja formule (I) su objavljena gde su R1-R7 kao što je definisano u prijavi i ona imaju dejstvo kao inhibitori vezivanja izmedju VCAM-1 i ćelija koje luče VLA-4 i stoga su korisna za tretiranje oboljenja čiji su simptomi ili oštećenja povezani sa vezivanjem VCAM-1 za ćelije koje luče VLA-4, kao što su hronična zapaljenska oboljenja.[Compounds of Formula (I) are disclosed wherein R1-R7 are as defined in the application and which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4 and, therefore, are useful for treating diseases whose symptoms and or damage are related to the binding of VCAM-1 to cells expressing VLA-4, such as chronic inflammatory diseases.
YU40502A 1999-12-06 2000-11-29 4-piridinil-n-acil-l-fenilalanini YU40502A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16909099P 1999-12-06 1999-12-06

Publications (1)

Publication Number Publication Date
YU40502A true YU40502A (sh) 2005-03-15

Family

ID=22614226

Family Applications (1)

Application Number Title Priority Date Filing Date
YU40502A YU40502A (sh) 1999-12-06 2000-11-29 4-piridinil-n-acil-l-fenilalanini

Country Status (34)

Country Link
EP (1) EP1244625B1 (sh)
JP (2) JP2003516392A (sh)
KR (1) KR100492111B1 (sh)
CN (1) CN1196682C (sh)
AR (1) AR031083A1 (sh)
AT (1) ATE297895T1 (sh)
AU (1) AU779063B2 (sh)
BR (1) BR0016172A (sh)
CA (1) CA2392566A1 (sh)
CO (1) CO5080771A1 (sh)
CZ (1) CZ20022352A3 (sh)
DE (1) DE60020883T2 (sh)
DK (1) DK1244625T3 (sh)
ES (1) ES2243335T3 (sh)
GC (1) GC0000214A (sh)
HK (1) HK1053470A1 (sh)
HR (1) HRP20020467A2 (sh)
HU (1) HUP0203735A3 (sh)
IL (2) IL149622A0 (sh)
JO (1) JO2281B1 (sh)
MA (1) MA26849A1 (sh)
MX (1) MXPA02005240A (sh)
MY (1) MY128003A (sh)
NO (1) NO322910B1 (sh)
NZ (1) NZ518888A (sh)
PE (1) PE20010960A1 (sh)
PL (1) PL364814A1 (sh)
PT (1) PT1244625E (sh)
RU (1) RU2270193C2 (sh)
TW (1) TWI276629B (sh)
UY (1) UY26470A1 (sh)
WO (1) WO2001042215A1 (sh)
YU (1) YU40502A (sh)
ZA (1) ZA200203762B (sh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
PT1288205E (pt) 2000-08-18 2011-05-06 Ajinomoto Kk Novos derivados de fenilalanina
JP4895067B2 (ja) * 2000-09-29 2012-03-14 味の素株式会社 新規フェニルアラニン誘導体
AU2002354224A1 (en) 2001-12-13 2003-07-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
CA2469435A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
ES2548853T3 (es) 2003-12-22 2015-10-21 Ajinomoto Co., Inc. Derivado de fenilalanina
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
AU2005277634B2 (en) * 2004-08-16 2011-02-17 Merck Sharp & Dohme Corp. VLA-4 antagonists
JP4784224B2 (ja) 2004-09-24 2011-10-05 味の素株式会社 糖鎖転移方法および糖鎖転移酵素
CA2641160A1 (en) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
TW200811164A (en) * 2006-05-12 2008-03-01 Jerini Ag New heterocyclic compounds for the inhibition of integrins and use thereof
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
EP2860260A1 (en) 2008-04-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
EP2456747B1 (de) * 2009-07-23 2014-06-25 Bayer CropScience AG Verfahren zur Herstellung von Alkoxyenonen und Enaminoketonen
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
KR20140127234A (ko) * 2012-01-27 2014-11-03 에프. 호프만-라 로슈 아게 Ｖｌａ-4 발현 세포로의 표적화된 전달을 위한 인테그린 안타고니스트 접합체
EP3008056B8 (en) * 2013-06-11 2021-03-03 Receptos Llc Novel glp-1 receptor modulators
JP6820282B2 (ja) 2016-02-05 2021-01-27 Ｅａファーマ株式会社 スルホンアミド誘導体及びそれを含有する医薬組成物
AU2019373244B2 (en) 2018-10-30 2022-05-26 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
BR112021007213A2 (pt) 2018-10-30 2021-08-10 Gilead Sciences, Inc. derivados de quinolina como inibidores de integrina alfa4beta7
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512625A (ja) * 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
CA2291762A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
DE69919334T2 (de) * 1998-02-26 2005-08-04 Celltech Therapeutics Ltd., Slough Phenylalaninderivate als inhibitoren von alpha4 integrinen
GB9811159D0 (en) * 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
JP2003524614A (ja) * 1998-12-22 2003-08-19 田辺製薬株式会社 α４β１媒介細胞接着のインヒビター
ATE299490T1 (de) * 1999-01-22 2005-07-15 Elan Pharm Inc Multizyklische verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion

Also Published As

Publication number Publication date
PT1244625E (pt) 2005-09-30
TWI276629B (en) 2007-03-21
NZ518888A (en) 2004-02-27
UY26470A1 (es) 2001-05-31
GC0000214A (en) 2006-03-29
KR100492111B1 (ko) 2005-06-01
RU2270193C2 (ru) 2006-02-20
BR0016172A (pt) 2002-08-20
HUP0203735A2 (hu) 2003-03-28
CZ20022352A3 (cs) 2003-05-14
JP2003516392A (ja) 2003-05-13
KR20020060256A (ko) 2002-07-16
AU2163901A (en) 2001-06-18
IL149622A (en) 2006-12-10
WO2001042215A1 (en) 2001-06-14
HK1053470A1 (en) 2003-10-24
ZA200203762B (en) 2004-01-28
ES2243335T3 (es) 2005-12-01
NO20022650L (no) 2002-06-05
NO322910B1 (no) 2006-12-18
DE60020883D1 (de) 2005-07-21
DK1244625T3 (da) 2005-10-10
CN1402709A (zh) 2003-03-12
JP2008094842A (ja) 2008-04-24
CA2392566A1 (en) 2001-06-14
HRP20020467A2 (en) 2004-04-30
AU779063B2 (en) 2005-01-06
HUP0203735A3 (en) 2005-03-29
MA26849A1 (fr) 2004-12-20
NO20022650D0 (no) 2002-06-05
MY128003A (en) 2007-01-31
AR031083A1 (es) 2003-09-10
PL364814A1 (en) 2004-12-13
IL149622A0 (en) 2002-11-10
MXPA02005240A (es) 2002-11-07
EP1244625B1 (en) 2005-06-15
DE60020883T2 (de) 2006-03-23
CO5080771A1 (es) 2001-09-25
JO2281B1 (en) 2005-09-12
EP1244625A1 (en) 2002-10-02
PE20010960A1 (es) 2001-09-22
ATE297895T1 (de) 2005-07-15
CN1196682C (zh) 2005-04-13

Similar Documents

Publication Publication Date Title
YU40502A (sh) 4-piridinil-n-acil-l-fenilalanini
TWI256387B (en) 4-pyrimidinyl-n-acyl-l-phenylalanines
MY138140A (en) N-aroylphenylalanine derivatives
MY129295A (en) N-alkanoylphenylalanine derivatives
PT1154993E (pt) Derivados de tioamida
IL143968A0 (en) Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
WO2000063234A3 (en) Pyrrolidincarbonylamino cyclic disulfides as vcam-vla4 antagonists
DE60140964D1 (en) Sphingolipiden
WO2006119402A3 (en) C-linked glucoronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth
ECSP982634A (es) Derivados de n- aroilofenil alanina